Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Updated

Aug. 01, 2019

Reviewed

Aug. 01, 2019

Appendix B: Panel Roster and Financial Disclosures

Mycobacterium avium Complex

Disseminated *Mycobacterium avium* Complex Disease
Member		Financial Disclosure
Member		Benson, Constance*	University of California, San Diego	Dr. Benson has served on an advisory and a data monitoring board for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. and DNA Electronics, Inc. Her spouse has served as a consultant to CytoDyn, Gilead Sciences, Inc, Pfizer, and Vir Biotechnology; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn.
* Group lead Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines

Section OnlyPDF (508.35 KB)
Full GuidelinePDF (3.78 MB)
Tables OnlyPDF (481.21 KB)